Samsung biopharma unit mulling Nasdaq listing to raise about US$1.34b
[SEOUL] Samsung Bioepis Co Ltd, a biopharma development unit of Samsung Group, is considering listing on the Nasdaq to raise about 1.5 trillion won (S$1.82 billion) to fund biopharma product development, a Bioepis spokeswoman said on Monday.
Samsung Group will soon send proposals to investment banks before choosing advisors for the IPO, potentially during the first half of 2016, newspaper Korea Economic Daily reported earlier on Monday, citing an industry source and an investment banking source, all unnamed.
The market capitalisation of Samsung Bioepis is expected to be at least 8 trillion won, the Korea Economic Daily said citing the investment banking source.
REUTERS
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself
Japan’s Uniqlo opens Rome store as part of European expansion